Merola, J., Sofen, H., Thaci, D., Paul, C., Imafuku, S., Banerjee, . S., & Armstrong , A. (2021). Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 5(6), s36.